Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ESTRONE vs ALORA
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.
Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.
Moderate to severe vasomotor symptoms associated with menopause,Vulvar and vaginal atrophy,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prevention of postmenopausal osteoporosis (off-label in some contexts),Prostate cancer (palliative therapy, off-label),Breast cancer (palliative therapy in selected cases, off-label)
Moderate to severe vasomotor symptoms due to menopause,Moderate to severe symptoms of vulvar and vaginal atrophy due to menopause,Hypoestrogenism due to hypogonadism, castration, or primary ovarian failure,Prostate cancer (palliative),Breast cancer (palliative, in selected cases),Postpartum breast engorgement (prevention)
For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.
Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.
Terminal elimination half-life is 24-36 hours; due to enterohepatic recirculation and slow clearance of conjugates, clinical effects persist for several days after discontinuation.
The terminal elimination half-life of estradiol is approximately 13-19 hours following transdermal administration, reflecting slow release from the skin depot and ongoing metabolism. This half-life allows for continuous hormone levels with once- or twice-weekly dosing.
Metabolized primarily in the liver via hydroxylation by cytochrome P450 enzymes (CYP3A4, CYP1A2, CYP2C9, CYP2C19) and conjugation to glucuronides and sulfates. Estrone is interconvertible with estradiol and estriol. Enterohepatic recirculation occurs.
Primarily hepatic via CYP3A4; undergoes enterohepatic recirculation; metabolites include estrone, estriol, and conjugates (glucuronides and sulfates).
Renal (approximately 60-80% as glucuronide and sulfate conjugates), biliary/fecal (20-40%)
Alora (estradiol transdermal system) is eliminated primarily via hepatic metabolism, with approximately 60% of a dose excreted in urine as glucuronide and sulfate conjugates, and about 40% excreted in feces via biliary elimination.
Approximately 96-98% bound to albumin and sex hormone-binding globulin (SHBG)
Estradiol is approximately 97-99% bound to serum proteins, primarily sex hormone-binding globulin (SHBG) and albumin. The binding to SHBG is high affinity, while albumin binding is nonspecific and lower affinity.
0.8-1.2 L/kg; indicates extensive distribution into tissues, particularly adipose tissue.
The apparent volume of distribution (Vd) of estradiol is approximately 5-10 L/kg, indicating extensive distribution into tissues including breast, adipose, and reproductive organs. This large Vd reflects sequestration in adipose tissue and other estrogen-sensitive tissues.
Oral: ~5% due to extensive first-pass metabolism; Intramuscular: 100%; Topical: variable, approximately 10% systemically.
The bioavailability of estradiol from the transdermal system is approximately 10% compared to oral administration, due to avoidance of first-pass hepatic metabolism. The absolute bioavailability relative to intravenous is near 100%, as transdermal delivery provides direct systemic absorption.
No specific dose adjustments provided; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of metabolites; monitor estrogenic effects.
No dose adjustment required for mild-moderate renal impairment (GFR >=30 m L/min). Not studied in severe impairment (GFR <30 m L/min); use with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In Child-Pugh class A or B, reduce dose by 50% and monitor liver function; start at lowest effective dose.
Contraindicated in severe hepatic disease (Child-Pugh class C). For moderate impairment (Child-Pugh class B), use lowest effective dose and monitor. No adjustment for mild (Child-Pugh class A).
Not indicated for routine use; individualize for rare conditions (e.g., delayed puberty) under specialist guidance. Typical starting dose: 0.3-0.625 mg orally once daily; adjust based on response and bone age.
Not approved for use in pediatric patients. Safety and efficacy not established.
Start at low end of dosing range (e.g., 0.3-0.625 mg orally once daily); consider increased risk of thromboembolism and endometrial cancer; monitor for adverse effects; use shortest duration possible.
Use lowest effective dose and duration. Consider increased risk of cardiovascular events, thromboembolism, and malignancy. Starting dose 0.025 mg/day with gradual titration as needed.
Estrogens increase the risk of endometrial cancer in postmenopausal women. Unopposed estrogen use is associated with increased risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures should be undertaken to rule out malignancy in cases of undiagnosed persistent or recurring abnormal vaginal bleeding.
Estrogens increase the risk of endometrial cancer. Unopposed estrogen increases the risk of endometrial hyperplasia and carcinoma. Adequate diagnostic measures, including endometrial sampling if indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding.
Cardiovascular disorders: Increased risk of stroke, DVT, pulmonary embolism, and myocardial infarction, especially in smokers and older women,Malignancy: Increased risk of endometrial cancer (unopposed estrogen) and potential for breast cancer; avoid use in known or suspected estrogen-dependent neoplasia,Dementia: Possible increased risk in women over 65 years,Gallbladder disease: Increased risk of cholelithiasis,Hypertriglyceridemia: May cause severe hypertriglyceridemia with pancreatitis,Hepatic impairment: Use with caution; may be contraindicated in severe disease,Fluid retention: May exacerbate conditions such as asthma, epilepsy, migraine, cardiac or renal dysfunction,Hypocalcemia: Should be used with caution in patients with hypoparathyroidism,Visual abnormalities: Discontinue if sudden vision loss, proptosis, or migraine develops
Cardiovascular disorders (e.g., stroke, DVT, pulmonary embolism), probable dementia (increased risk in women ≥65 years), breast cancer, endometrial cancer, gallstones, hypertriglyceridemia, fluid retention, hypocalcemia, hereditary angioedema, and exacerbation of endometriosis.
Known or suspected pregnancy,Undiagnosed abnormal genital bleeding,Known or suspected breast cancer (except in selected palliative cases),Known or suspected estrogen-dependent neoplasia,Active or history of venous thromboembolism (e.g., DVT, pulmonary embolism),Active arterial thromboembolic disease (e.g., stroke, MI),Severe hepatic impairment or disease,Hypersensitivity to estrone or any component of the formulation
Undiagnosed abnormal genital bleeding, known/suspected pregnancy, known/suspected breast cancer (except in selected cases), known/suspected estrogen-dependent neoplasia, active DVT/PE or history of these conditions, active arterial thromboembolic disease, known protein C/protein S/antithrombin deficiency or other thrombophilic disorders, liver dysfunction or disease, known hypersensitivity to estradiol or any component.
Grapefruit and grapefruit juice may inhibit estrone metabolism, increasing serum levels and risk of adverse effects. Avoid concomitant high-fat meals as they may alter absorption. No other significant food interactions reported. Maintain adequate calcium and vitamin D intake for bone health.
No significant food interactions. Avoid grapefruit juice if on hormonal therapy as it may increase estrogen levels.
First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tract abnormalities and potential for other adverse effects. Overall: FDA Pregnancy Category X (contraindicated) unless used for specific conditions like progesterone-resistant recurrent pregnancy loss.
ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in female offspring, as well as congenital anomalies including cardiac defects and limb reduction defects. Second and third trimesters: increased risk of fetal genital abnormalities and potential for long-term reproductive tract effects. Estrogens are not indicated for use during pregnancy.
Estrone is excreted in human breast milk; M/P ratio not determined. Use during lactation is generally contraindicated as estrogens may suppress milk production and alter milk composition. Alternative agents recommended if breastfeeding.
Estradiol is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.1-0.2. ALORA may reduce milk production and quality due to estrogenic effects. Use during breastfeeding is not recommended. If used, monitor the infant for signs of estrogen exposure such as breast enlargement or vaginal bleeding.
No recommended dosing in pregnancy due to contraindication; if used, no established dose adjustments exist. Estrogen clearance is increased in pregnancy, but systematic data for estrone are lacking; generally, avoidance is advised.
ALORA is contraindicated in pregnancy; no dosing adjustments are applicable. The physiological increase in estrogen-binding proteins and hepatic clearance during pregnancy would theoretically reduce efficacy if used, but use is prohibited due to teratogenicity.
Estrone is primarily used in menopausal hormone therapy and has weak estrogenic activity compared to estradiol. Monitor for endometrial hyperplasia in women with an intact uterus; concurrent progestin is required. Assess thromboembolic risk before initiation. Estrone may be less effective for vasomotor symptoms than estradiol. Avoid in patients with breast cancer, liver disease, or undiagnosed vaginal bleeding.
ALORA 0.03% estradiol vaginal cream is indicated for atrophic vaginitis. Apply 1-2 g daily for 2 weeks, then taper. May cause endometrial hyperplasia if used without progestin in women with intact uterus. Avoid in breast cancer history.
Take estrone exactly as prescribed; do not alter dose or frequency.,Report any unusual vaginal bleeding, breast lumps, or jaundice immediately.,Estrone does not protect against HIV or other sexually transmitted infections.,You may experience nausea, headache, or breast tenderness; contact your doctor if severe.,Do not use estrone if you are pregnant, think you might be pregnant, or are breastfeeding.,Avoid smoking and excessive alcohol consumption to reduce cardiovascular risks.
Use the measured applicator for correct dose.,Apply cream at bedtime for best absorption.,Wash applicator after each use with soap and water.,Report any abnormal vaginal bleeding immediately.,Do not use if allergic to estrogens.
"Almasilate, a magnesium-aluminum antacid, can adsorb estrone in the gastrointestinal tract, reducing its absorption and systemic bioavailability. This interaction may lead to subtherapeutic estrone levels, potentially diminishing its therapeutic effects in hormone replacement therapy. Patients may experience inadequate symptom control or hormonal imbalance if the drugs are taken concomitantly without proper timing separation."
"Clarithromycin is a potent CYP3A4 inhibitor and also inhibits P-glycoprotein, significantly decreasing the clearance of estrone, which is metabolized via CYP3A4 and transported by P-gp. This leads to elevated estrone plasma concentrations, increasing estrogenic effects such as thromboembolic risk, breast tenderness, and endometrial proliferation. Clinical vigilance is warranted, especially in patients on hormone replacement therapy or using estrone for menopausal symptoms, as coadministration may precipitate estrogen-related adverse events."
"Estrone, an estrogen hormone, may induce the expression of UDP-glucuronosyltransferase (UGT) enzymes, which are involved in the glucuronidation and subsequent clearance of afatinib. This induction can lead to a decrease in afatinib serum concentrations, potentially reducing its efficacy in the treatment of non-small cell lung cancer. Clinically, this interaction may result in suboptimal therapeutic outcomes unless the afatinib dose is adjusted."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ESTRONE vs ALORA, answered by our medical review team.
ESTRONE is a Estrogen that works by Estrone is a natural estrogen that binds to estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and exerting estrogenic effects on reproductive, skeletal, and cardiovascular systems.. ALORA is a Estrogen that works by Estradiol binds to estrogen receptors (ERα and ERβ), activating gene transcription and non-genomic signaling pathways, resulting in proliferation of endometrial tissue.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ESTRONE and ALORA depend on the specific clinical indication. These are both Estrogen agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ESTRONE is: For menopausal hormone therapy: 0.625-5 mg orally once daily; or 0.1-0.5 mg transdermally once weekly; or 2.5-5 mg intramuscularly every 2-4 weeks.. The standard adult dose of ALORA is: Estradiol (ALORA) transdermal patch: 0.025-0.1 mg/day applied twice weekly. Typical starting dose 0.05 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ESTRONE and ALORA in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ESTRONE is classified as Category C. First trimester: Theoretical risk of fetal harm based on estrogenic effects, but no well-controlled studies. Second and third trimesters: Avoid use due to risk of fetal genital tra. ALORA is classified as Category C. ALORA (estradiol vaginal ring) is contraindicated in pregnancy. First trimester: estrogen exposure is associated with a risk of vaginal adenosis and clear cell adenocarcinoma in fe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.